Primary seminal vesicle adenocarcinoma (PSVA) is an extremely rare disease without any unified diagnostic criterion. Differential diagnosis of PSVA from prostate cancer, colon cancer, and bladder cancer is necessary but difficult because of the lack of standard management. Radical resection is considered the mainstay of primary treatment that offers satisfactory prognosis. Most cases with PSVA are diagnosed at advanced stages because its early manifestation is nonspecific and it is rarely diagnosed in clinic. In this study, we described the case of a 52 year-old PSVA patient who was treated at the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, in July 2012. The patient underwent local excision, with tumor residuals visible under the naked eye. The patient benefits from a six-cycle paclitaxel (175 mg/m2) therapeutic regimen combined with cisplatin (60 mg/m2), as well as pelvic modulated radiotherapy with a radiation dose of 60 Gy/30 F. At present, the patient is disease-free and undergoes regular follow-up.
- Seminal vesicle adeno-carcinoma
ASJC Scopus subject areas
- Cancer Research